• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Mevacor (lovastatin)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

February 2014

Summary View

CONTRAINDICATIONS

  • Added…cobicistat-containing products

WARNINGS

Strong inhibitors of CYP3A4:
  • Added…cobicistat-containing products
Table VII
  • Added…cobicistat-containing products

PRECAUTIONS

Information for Patients

Drug Interactions

CYP3A4 Interactions

  • Added…cobicistat-containing products